Voriconazole CAS 137234-62-9

Voriconazole CAS 137234-62-9: Comprehensive Product Guide

Table of Contents

• 1. Product Overview & Specifications
• 2. Key Applications & Therapeutic Uses
• 3. Clinical Case Studies
• 4. Industry Adoption & Client Success Stories
• 5. Technical Support & Inquiry Guidance

1. Product Overview & Specifications

2. Key Applications & Therapeutic Uses

Medical Applications

• First-line treatment for invasive aspergillosis (success rate: 52.8% vs amphotericin B’s 31.6%)
• Candidemia in non-neutropenic patients (ICU mortality reduction: 15.2% with voriconazole vs 22.2% standard care)
• Prophylaxis in hematopoietic stem cell transplant recipients

Research Applications

• Antifungal resistance studies (MIC90 values: 0.5-1 μg/ml for Candida albicans)
• Drug interaction research (CYP2C19/CYP3A4 enzyme studies)

3. Clinical Case Studies

Case 1: Pulmonary Aspergillosis

Patient: 58yo male with AML
Regimen: 6 mg/kg IV q12h ×24hrs → 4 mg/kg maintenance
Outcome: Radiological improvement in 72% lesions at 14 days

Case 2: Breakthrough Candidemia

Patient: 34yo post-liver transplant
Regimen: 200mg PO q12h + therapeutic drug monitoring
Outcome: Blood culture negativity achieved in 96 hrs

4. Industry Adoption & Client Success Stories

Client 1: European Pharma Manufacturer

• Annual procurement: 850kg voriconazole API
• Application: Generic VFEND® production
• Batch consistency: 99.92-100.08% potency across 36 lots

Client 2: US Research Hospital

• Usage: Antifungal stewardship program
• Outcome: 41% reduction in azole-resistant Candida cases
• Cost savings: $2.8M/year through optimized dosing protocols

5. Technical Support & Inquiry Guidance

For formulation development support or bulk procurement quotes:
Email: info@vivalr.com
Tel: (86) 15866781826

Why Choose Us?

• ISO 9001-certified manufacturing
• Strict 99.5%+ purity control (ICH Q3D elemental limits)
• Global logistics network (DDU/DDP Incoterms available)